Fulgent Genetics to Announce Second Quarter 2020 Financial Results on Tuesday August 4, 2020

Rhea-AI Summary

Fulgent Genetics (NASDAQ: FLGT) will release its Q2 2020 financial results on August 4, 2020, after market close. A conference call will follow at 4:30 PM ET to discuss results. The call can be accessed through a live audio webcast on the company’s website or by dialing (855) 321-9535 with conference ID 2797888. The company focuses on offering extensive genetic testing services, featuring a proprietary technology platform to deliver high-quality diagnostic information. Their test menu includes around 18,000 single-gene tests and over 850 multi-gene panels.

Positive

• Leading test menu with approximately 18,000 single-gene tests.
• Over 850 multi-gene, disease-specific panels available.
• Proprietary technology platform enhances test accuracy and turnaround times.

Negative

• None.

TEMPLE CITY, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 2797888. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 2797888 through August 11, 2020.

About Fulgent Genetics

Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Relations Contacts:
The Blueshirt Group
Melanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

FAQ

What are the expected financial results for Fulgent Genetics Q2 2020?

Fulgent Genetics will release its financial results for Q2 2020 on August 4, 2020, after market close.

What is the significance of Fulgent Genetics' upcoming conference call?

The conference call on August 4, 2020, at 4:30 PM ET will provide insights into the company's financial performance and future outlook.

How can I access the Fulgent Genetics conference call?

You can access the call via a live audio webcast on the company's website or by dialing (855) 321-9535 with the conference ID 2797888.

What services does Fulgent Genetics offer?

Fulgent Genetics provides comprehensive genetic testing with a focus on clinically actionable diagnostic information.